{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:31:34Z","timestamp":1794479494123,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001738","name":"Ministry of Innovation, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013043","name":"Ariel University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114993","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:20:38Z","timestamp":1778080838000},"page":"114993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Toward targeting the untargetable: A non-canonical EGFR-peptide\u2013drug conjugate achieves potent antitumor activity in KRAS-mutant CRC"],"prefix":"10.1016","volume":"395","author":[{"given":"Shachar","family":"Ayali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Panja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashaswi","family":"Dutta Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Tobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrii","family":"Bazylevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet Rosenberg","family":"Ayale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elimelech","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Gellerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bat Chen R.","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2026.114993_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"27","key":"10.1016\/j.jconrel.2026.114993_bb0015","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","article-title":"Colorectal peritoneal metastases: optimal management review","volume":"25","author":"S\u00e1nchez-Hidalgo","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114993_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164922","article-title":"Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer","volume":"11","author":"Mendoza-Moreno","year":"2022","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114993_bb0025","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.jconrel.2026.114993_bb0030","doi-asserted-by":"crossref","first-page":"30787","DOI":"10.18632\/oncotarget.5021","article-title":"Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy","volume":"6","author":"Alves","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114993_bb0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jclinpath-2018-205471","article-title":"RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications","volume":"72","author":"Saeed","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2026.114993_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111717","article-title":"The current understanding on the impact of KRAS on colorectal cancer","volume":"140","author":"Meng","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114993_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100156","article-title":"Strategies to tackle RAS-mutated metastatic colorectal cancer","volume":"6","author":"Patelli","year":"2021","journal-title":"ESMO Open."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114993_bb0050","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114993_bb0055","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114993_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-024-00793-6","article-title":"Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization","volume":"9","author":"Maruyama","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.jconrel.2026.114993_bb0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2017.08.040","article-title":"Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells","volume":"408","author":"Bashari","year":"2017","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114993_bb0070","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/pharmaceutics14071505","article-title":"Novel cyclic peptides for targeting EGFR and EGRvIII mutation for drug delivery","volume":"14","author":"Furman","year":"2022","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114993_bb0075","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/pharmaceutics16121613","article-title":"Novel cyclic peptide-drug conjugate P6-SN38 toward targeted treatment of EGFR overexpressed non-small cell lung cancer","volume":"16","author":"Bazylevich","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114993_bb0080","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/932932","article-title":"EGFR signaling in colorectal carcinoma","volume":"2011","author":"Krasinskas","year":"2011","journal-title":"Pathol. Res. Int."},{"key":"10.1016\/j.jconrel.2026.114993_bb0085","author":"Bank RPD"},{"key":"10.1016\/j.jconrel.2026.114993_bb0090","author":"Bank RPD"},{"issue":"7","key":"10.1016\/j.jconrel.2026.114993_bb0100","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114993_bb0105","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1063\/1.463940","article-title":"Nos\u00e9\u2013Hoover chains: the canonical ensemble via continuous dynamics","volume":"97","author":"Martyna","year":"1992","journal-title":"J. Chem. Phys."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114993_bb0110","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","volume":"49","author":"Lyne","year":"2006","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114993_bb0115","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.jconrel.2026.114993_bb0120","author":"Prodigy Webserver"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114993_bb0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12885-021-07823-7","article-title":"Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis","volume":"21","author":"Kawai","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114993_bb0130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and Cetuximab with or without Vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114993_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1356708","article-title":"The effective combination therapies with irinotecan for colorectal cancer","volume":"15","author":"Chai","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114993_bb0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/bmc.1345","article-title":"Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives","volume":"24","author":"Ramesh","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114993_bb0145","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ijc.28550","article-title":"KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells","volume":"134","author":"Nakadate","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114993_bb0150","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/ijc.32618","article-title":"CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab","volume":"146","author":"Arriga","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114993_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0169-5002(03)00223-X","article-title":"Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer","volume":"41","author":"Ohtsuka","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jconrel.2026.114993_bb0160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/IJN.S435407","article-title":"Research progress of SN38 drug delivery system in cancer treatment","volume":"19","author":"Qi","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114993_bb0165","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114993_bb0170","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114993_bb0175","first-page":"54","article-title":"Smart stimuli-responsive carrier-free nanoassembly of SN38 prodrug as efficient chemotherapeutic nanomedicine","volume":"2","author":"Li","year":"2023","journal-title":"Acta Mater. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114993_bb0180","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1007\/s11426-025-2760-2","article-title":"Dual advantages of SN38 prodrug nanoassemblies overcome defects of irinotecan and SN38: enhanced stability and activatability","volume":"68","author":"Xing","year":"2025","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.jconrel.2026.114993_bb0185","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2147\/IJN.S404848","article-title":"Disulfide bond-based SN38 prodrug nanoassemblies with high drug loading and reduction-triggered drug release for pancreatic cancer therapy","volume":"18","author":"Zhong","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114993_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.biomaterials.2015.11.055","article-title":"SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery","volume":"79","author":"Monterrubio","year":"2016","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114993_bb0195","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.21873\/anticanres.17252","article-title":"Therapeutic responses to two new SN-38 derivatives in colorectal cancer patient-derived xenografts and respective 3D in vitro cultures","volume":"44","author":"Unrug-Bielawska","year":"2024","journal-title":"Anticancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:59:46Z","timestamp":1794477586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"alternative-id":["S0168365926003962"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114993","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward targeting the untargetable: A non-canonical EGFR-peptide\u2013drug conjugate achieves potent antitumor activity in KRAS-mutant CRC","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114993"}}